WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:   || 2 | 3 |

«DESCRIPTION Azmacort Proprietary name: Triamcinolone acetonide Established name: RESPIRATORY (INHALATION) (C38216) Route of administration: ...»

-- [ Page 1 ] --

Azmacort®

(triamcinolone acetonide)

Inhalation Aerosol

Rx Only

For Oral Inhalation Only

Shake Well Before Using

DESCRIPTION

Azmacort

Proprietary name:

Triamcinolone acetonide

Established name:

RESPIRATORY (INHALATION) (C38216)

Route of administration:

Triamcinolone acetonide (Triamcinolone)

Active ingredients (moiety):

# Strength Form Inactive ingredients 1 60 MILLIGRAM AEROSOL, METERED (C42960) Dehydrated alcohol, dichlorodifluoromethane Triamcinolone acetonide, USP, the active ingredient in Azmacort® Inhalation Aerosol, is a corticosteroid with a molecular weight of 434.5 and with the chemical designation 9- Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone. (C24H31FO6).

Azmacort Inhalation Aerosol is a metered-dose aerosol unit containing a microcrystalline suspension of triamcinolone acetonide in the propellant dichlorodifluoromethane and dehydrated alcohol USP 1% w/w. Each canister contains 60 mg triamcinolone acetonide.

The canister must be primed prior to the first use. After an initial priming of 2 actuations, each actuation delivers 200 mcg triamcinolone acetonide from the valve and 75 mcg from the spacer-mouthpiece under defined in vitro test conditions. The canister will remain primed for 3 days. If the canister is not used for more than 3 days, then it should be reprimed with 2 actuations. There are at least 240 actuations in one Azmacort Inhalation Aerosol canister. After 240 actuations, the amount delivered per actuation may not be consistent and the unit should be discarded.

CLINICAL PHARMACOLOGY

Triamcinolone acetonide is a more potent derivative of triamcinolone. Although triamcinolone itself is approximately one to two times as potent as prednisone in animal models of inflammation, triamcinolone acetonide is approximately 8 times more potent than prednisone.

The precise mechanism of the action of glucocorticoids in asthma is unknown. However, the inhaled route makes it possible to provide effective local anti-inflammatory activity with reduced systemic corticosteroid effects. Though highly effective for asthma, glucocorticoids do not affect asthma symptoms immediately. While improvement in asthma may occur as soon as one week after initiation of Azmacort Inhalation Aerosol therapy, maximum improvement may not be achieved for 2 weeks or longer.

Based upon intravenous dosing of triamcinolone acetonide phosphate ester, the half-life of triamcinolone acetonide was reported to be 88 minutes. The volume of distribution (Vd) reported was 99.5 L (SD ± 27.5) and clearance was 45.2 L/hour (SD ± 9.1) for triamcinolone acetonide. The plasma half-life of glucocorticoids does not correlate well with the biologic half-life.

The pharmacokinetics of radiolabeled triamcinolone acetonide [14C] were evaluated following a single oral dose of 800 mcg to healthy male volunteers. Radiolabeled triamcinolone acetonide was found to undergo relatively rapid absorption following oral administration with maximum plasma triamcinolone acetonide and [14C]-derived radioactivity occurring between 1.5 and 2 hours. Plasma protein binding of triamcinolone acetonide appears to be relatively low and consistent over a wide plasma triamcinolone acetonide concentration range as a function of time. The overall mean percent fraction bound was approximately 68%.

The metabolism and excretion of triamcinolone acetonide were both rapid and extensive with no parent compound being detected in the plasma after 24 hours post-dose and a low ratio (10.6%) of parent compound AUC0-∞ to total [14C] radioactivity AUC0-∞. Greater than 90% of the oral [14C]-radioactive dose was recovered within 5 days after administration in 5 out of the 6 subjects in the study. Of the recovered [14C]-radioactivity, approximately 40% and 60% were found in the urine and feces, respectively.

Three metabolites of triamcinolone acetonide have been identified. They are 6βhydroxytriamcinolone acetonide, 21-carboxytriamcinolone acetonide and 21-carboxy-6βhydroxytriamcinolone acetonide. All three metabolites are expected to be substantially less active than the parent compound due to (a) the dependence of anti-inflammatory activity on the presence of a 21-hydroxyl group, (b) the decreased activity observed upon 6-hydroxylation, and (c) the markedly increased water solubility favoring rapid elimination.

There appeared to be some quantitative differences in the metabolites among species. No differences were detected in metabolic pattern as a function of route of administration.

CLINICAL TRIALS

Double-blind, placebo-controlled efficacy and safety studies have been conducted in asthma patients with a range of asthma severities, from those patients with mild disease to those with severe disease requiring oral steroid therapy.

The efficacy and safety of Azmacort Inhalation Aerosol given twice daily was demonstrated in two placebo-controlled clinical trials. In two separate studies, 222 asthmatic patients were randomized to receive either Azmacort Inhalation Aerosol 300 mcg twice daily or matching placebo for a treatment period of 6 weeks. Patients were adult asthmatics who were using inhaled beta2-agonists on more than an occasional basis (at least three times weekly), either without or with inhaled corticosteroids, for control of their asthma symptoms. For the combined studies, 48% (52/109) patients randomized to placebo and 41% (46/113) patients randomized to Azmacort Inhalation Aerosol treatment were previously treated with inhaled corticosteroids.





–  –  –

aEndpoint results are obtained from the last evaluable data, regardless of whether the patient completed 6 weeks of treatment bScale (0-6) with 0 = no symptom: Maximum Score (AM + PM) =12 In both studies, treatment with Azmacort Inhalation Aerosol (300 mcg twice daily) resulted in significant improvements in all clinical asthma measures (lung functions, asthma symptoms, use of as-needed beta2-agonist medications) when compared to placebo.

INDICATIONS

Azmacort Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy. Azmacort Inhalation Aerosol is also indicated for asthma patients who require systemic corticosteroid administration, where adding Azmacort may reduce or eliminate the need for the systemic corticosteroids.

Azmacort Inhalation Aerosol is NOT indicated for the relief of acute bronchospasm.

CONTRAINDICATIONS

Azmacort Inhalation Aerosol is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.

Hypersensitivity to triamcinolone acetonide or any of the other ingredients in this preparation contraindicates its use.

WARNINGS Particular care is needed in patients who are transferred from systemically active corticosteroids to Azmacort Inhalation Aerosol because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to aerosolized steroids in recommended doses. After withdrawal from systemic corticosteroids, a number of months is usually required for recovery of hypothalamic-pituitary-adrenal (HPA) function. For some patients who have received large doses of oral steroids for long periods of time before therapy with Azmacort Inhalation Aerosol is initiated, recovery may be delayed for one year or longer. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, or infections, particularly gastroenteritis or other conditions with acute electrolyte loss. Although Azmacort Inhalation Aerosol may provide control of asthmatic symptoms during these episodes, in recommended doses it supplies only normal physiological amounts of corticosteroid systemically and does NOT provide the increased systemic steroid which is necessary for coping with these emergencies.

During periods of stress or a severe asthmatic attack, patients who have been recently withdrawn from systemic corticosteroids should be instructed to resume systemic steroids (in large doses) immediately and to contact their physician for further instruction. These patients should also be instructed to carry a warning card indicating that they may need supplementary systemic steroids during periods of stress or a severe asthma attack.

Localized infections with Candida albicans have occurred infrequently in the mouth and pharynx. These areas should be examined by the treating physician at each patient visit.

The percentage of positive mouth and throat cultures for Candida albicans did not change during a year of continuous therapy. The incidence of clinically apparent infection is low (2.5%). These infections may disappear spontaneously or may require treatment with appropriate antifungal therapy or discontinuance of treatment with Azmacort Inhalation Aerosol.

Children who are on immunosuppressant drugs are more susceptible to infections than healthy children. Chickenpox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant doses of corticosteroids. In such children, or in adults who have not had these diseases, particular care should be taken to avoid exposure. If exposed, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If chickenpox develops, treatment with antiviral agents may be considered.

Azmacort Inhalation Aerosol is not to be regarded as a bronchodilator and is not indicated for rapid relief of bronchospasm.

As with other inhaled asthma medications, bronchospasm may occur with an immediate increase in wheezing following dosing. If bronchospasm occurs following use of Azmacort Inhalation Aerosol, it should be treated immediately with a fast-acting inhaled bronchodilator. Treatment with Azmacort Inhalation Aerosol should be discontinued and alternative treatment should be instituted.

Patients should be instructed to contact their physician immediately when episodes of asthma which are not responsive to bronchodilators occur during the course of treatment with Azmacort Inhalation Aerosol. During such episodes, patients may require therapy with systemic corticosteroids.

The use of Azmacort Inhalation Aerosol with systemic prednisone, dosed either daily or on alternate days, could increase the likelihood of HPA suppression compared to a therapeutic dose of either one alone. Therefore, Azmacort Inhalation Aerosol should be used with caution in patients already receiving prednisone treatment for any disease.

Transfer of patients from systemic steroid therapy to Azmacort Inhalation Aerosol may unmask allergic conditions previously suppressed by the systemic steroid therapy, e.g., rhinitis, conjunctivitis, and eczema.

PRECAUTIONS

Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to pediatric patients (see PRECAUTIONS, Pediatric Use Because of the possibility of Use).

systemic absorption of inhaled corticosteroids, patients treated with these drugs should be observed carefully for any evidence of systemic corticosteroid effects including suppression of growth in children. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of a decrease in adrenal function.

During withdrawal from oral steroids, some patients may experience symptoms of systemically active steroid withdrawal, e.g., joint and/or muscular pain, lassitude, and depression, despite maintenance or even improvement of respiratory function. (See DOSAGE AND ADMINISTRATION Although steroid withdrawal effects are usually ADMINISTRATION.) transient and not severe, severe and even fatal exacerbation of asthma can occur if the previous daily oral corticosteroid requirement had significantly exceeded 10 mg/day of prednisone or equivalent.

In responsive patients, inhaled corticosteroids will often permit control of asthmatic symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since triamcinolone acetonide is absorbed into the circulation and can be systemically active, the beneficial effects of Azmacort Inhalation Aerosol in minimizing or preventing HPA dysfunction may be expected only when recommended dosages are not exceeded.

Suppression of HPA function has been reported in volunteers who received 4000 mcg daily of triamcinolone acetonide by oral inhalation. In addition, suppression of HPA function has been reported in some patients who have received recommended doses for as little as 6 to 12 weeks. Since the response of HPA function to inhaled corticosteroids is highly individualized, the physician should consider this information when treating patients.

When used at excessive doses or at recommended doses in a small number of susceptible individuals, systemic corticosteroid effects such as hypercorticoidism and adrenal suppression may appear. If such changes occur, Azmacort ® Inhalation Aerosol should be discontinued slowly, consistent with accepted procedures for reducing systemic steroid therapy and for management of asthma symptoms.

Azmacort Inhalation Aerosol should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, parasitic, or viral infections; or ocular herpes simplex.

The long-term local and systemic effects of Azmacort Inhalation Aerosol in human subjects are still not fully known. While there has been no clinical evidence of adverse experiences, the effects resulting from chronic use of Azmacort Inhalation Aerosol on developmental or immunologic processes in the mouth, pharynx, trachea, and lung are unknown.

Information for Patients: Patients being treated with Azmacort Inhalation Aerosol should receive the following information and instructions. This information is intended to aid them in the safe and effective use of this medication. It is not a complete disclosure of all possible adverse or intended effects.



Pages:   || 2 | 3 |


Similar works:

«United Nations Development Programme Human Development Report Office OCCASIONAL PAPER Background paper for HDR 2004 African Wars and Ethnic Conflicts – Rebuilding Failed States Kwesi Kwaa Prah 2004/10 African Wars and Ethnic Conflicts – Rebuilding Failed States Kwesi Kwaa Prah The Centre for Advanced Studies of African Society Cape Town Africa Regional Background Paper: Human Development Report 2004. UNDP. Introduction There has been a popular misconception that Africa’s numerous wars and...»

«Modern Judaism Advance Access published February 24, 2012 Marianna Ruah-Midbar CURRENT JEWISH SPIRITUALITIES IN ISRAEL: A NEW AGE1 Downloaded from http://mj.oxfordjournals.org/ by guest on February 25, 2012 INTRODUCTION—CURRENT SPIRITUALITIES IN ISRAEL Recently, new spiritualities have been emerging in Israel, which combine Judaism and New Age spirituality. Surprisingly, these interesting phenomena are being overlooked by academic and public discourse regarding Jewish spiritual innovations....»

«If someone you know is experiencing Domestic Abuse November 2013 Note: To both reflect the overwhelming majority and for ease of reading, this document refers to victims/survivors of domestic abuse as female, and perpetrators as male. However, this is not meant to imply that domestic abuse does not occur in same-sex relationships, or by women to men. If after reading this leaflet you need further information, please try: National Domestic Violence Helpline 0808 2000 247 Women’s Aid...»

«Last Updated: October 20, 2016 Ultimate Africa DAUA 54 days: Cape Town to Nairobi What's Included • Entrance to Fish River Canyon, Sossusvlei Dunes, and Spitzkoppe • Entrances and game drives in Etosha, Serengeti, and Lake Nakuru national parks • Guided township tour (Swakopmund) • Okavango Delta overnight bush camping excursion • Ngorongoro Crater visit with game drives • Guided tour of spice plantation (Zanzibar) • 4-day Zanzibar excursion • Guided mountain gorilla trek with...»

«CURRICULUM VITAE Young Yun Kim, Ph.D. Department of Communication, University of Oklahoma, Norman, OK 73019 Phone: 405/325-1587. Fax: 405/325-7625. E-mail: youngkim@ou.edu EDUCATION 1976 Ph. D., Communication, Northwestern University, Evanston, IL. Dissertation: Communication patterns of foreign immigrants in the process of acculturation 1972 M.A., Speech Communication, University of Hawaii, Honolulu. In conjunction with East-West Communication Institute. Thesis: Comparative content analysis of...»

«2011-4436 2012-02-22 Container Label GROUP 3 INSECTICIDE DRAGNET FT Emulsifiable Concentrate Insecticide COMMERCIAL FOR USE ONLY BY LICENSED PEST CONTROL OPERATORS REGISTRATION NO. 24175 PEST CONTROL PRODUCTS ACT CANADIAN PATENT NO: 1,008,455 GUARANTEE: Permethrin ** 384 g/L ** 55% Maximum cis ** 45% Minimum trans Store above 5°C READ THE LABEL AND ATTACHED LEAFLET BEFORE USING (See the First Aid and Precaution statements on rear panel) KEEP OUT OF REACH OF CHILDREN CAUTION POISON NET...»

«Picosecond Time-Resolved Photothermalization Process in Liquid Phase Toshiya Okazaki Department of Chemistry Graduate School of Science Kyoto University 1999. Contents page 1. General Introduction 1 2. Thermalization Process of Intramolecular Proton Transfer Systems Studied by the Transient Grating Method 2-1. Introduction 6 2-2. Experimental 8 2-3. Analysis 10 2-4. Results HMPB in cyclohexane 2-4-1. 15 HBP in non-hydrogen bonding solvents 2-4-2. 18 HBP in hydrogen bonding solvent 2-4-3. 18...»

«EstEla Mara BEnsiMon / Presidential Address 441 The Review of Higher Education Summer 2007, Volume 30, No. 4, pp. 441–469 Copyright © 2007 Association for the Study of Higher Education All Rights Reserved (ISSN 0162-5748) PRESIDENTIAL ADDRESS The Underestimated Significance of Practitioner Knowledge in the Scholarship on Student Success Estela Mara Bensimon In June of 2006, along with several colleagues from the New England Resource Center for Higher Education at the University of...»

«Advances in Anthropology, 2014, 4, 164-167 Published Online August 2014 in SciRes. http://www.scirp.org/journal/aa http://dx.doi.org/10.4236/aa.2014.43020 Removing the “Hermetic Seal” from the Aquatic Ape Hypothesis: Waterside Hypotheses of Human Evolution Algis V. Kuliukas University of Western Australia, Perth, Australia Email: algis.kuliukas@uwa.edu.au Received 26 April 2014; revised 21 May 2014; accepted 15 June 2014 Copyright © 2014 by author and Scientific Research Publishing Inc....»

«PIT SIGNALS LATE BRAKING NEWS FOR THE VARACVINTAGE RACER By JEREMY SALE APRIL 2014 The Cheetah turns 50! The Cheetah was one wicked race car! With a wheel base of 90 inches and only weighing 1,510 lbs this 1964 example has 420 bhp to make life more than interesting! Story and photos inside. The High Park Grand Prix “The Toronto Telegram contacted me and wanted to run the article. When they did a big spread on it, that is when the drivers lost their licenses! For over 40 years I did the...»

«People's Democratic Republic of Algeria Ministry of Higher Education and Scientific Research Mentouri University Constantine Faculty of Letters and Languages Department of English Flouting Grice’s Maxims _ A Pragmatic Study_ Case Study; Mentouri University, Constantine Dissertation Submitted in Partial Fulfilment of the Requirements for the “Master” Degree in Applied Language Studies. Board of Examiners President: Dr. Saleh KAOUACHE University of Constantine Supervisor: Dr. Riad BELOUAHEM...»

«Oral HPV: An Overview of the Disease and its Role in the Development of Oral Cancer What is oral HPV? Oral HPV (human papillomavirus) is a clinical manifestation of the HPV infection in regions of the ororespiratory tract, which includes the entire oropharyngeal complex, tongue, tonsils, and buccal and lingual mucosa. HPV is one of the most common sexually transmitted diseases in the United States.1-3 The prevalence of HPV is large and growing; according to the National Institute of Allergy and...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.